A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies-Reference-Cited by-同舟云学术

A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

Published:2024-01 Issue:1 Volume:13 Page:173-187
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Moullan Norman,Asiago Josephat,Stecco Kathryn,Hadi Salah,Albizem Moetaz,Tieu Holly,Hock Björn,Fenwick Craig,Lin Kai,Lengsfeld Thomas,Poffenbarger Lauren,Liu David,Trono Didier,Pantaleo Giuseppe,Venkayya Rajeev,Bhuyan Prakash^ORCID

Funder

Aerium Therapeutics

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40121-023-00908-9.pdf

Reference25 articles.

1. Fenwick C, Turelli P, Ni D, et al. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. Nat Microbiol. 2022;7(9):1376–89.

2. Fenwick C, Turelli P, Perez L, et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep. 2021;37(2):109814.

3. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–9.

4. Shrestha LB, Tedla N, Bull RA. Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants. Front Immunol. 2021;12:752003.

5. Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–7.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19;Expert Opinion on Biological Therapy;2024-08-02

2. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2;Clinical Microbiology and Infection;2024-08

3. HPLC–MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum;Analytical and Bioanalytical Chemistry;2024-06-21